Filtered By:
Therapy: Statin Therapy
This page shows you your search results in order of date. This is page number 11.
Order by Relevance | Date
Total 4067 results found since Jan 2013.
Dyslipidemia
Ann Intern Med. 2023 Jun 13. doi: 10.7326/AITC202306200. Online ahead of print.ABSTRACTDyslipidemia is an important risk factor for coronary artery disease and stroke. All persons with dyslipidemia should be advised to focus on lifestyle interventions, including regular aerobic exercise, a healthy diet, maintenance of a healthy weight, and abstinence from smoking. In addition to lifestyle interventions, lipid-lowering therapy should be considered for persons at moderate to high risk for atherosclerotic cardiovascular disease based on validated risk equations. Statin therapy is the first-line medical treatment for dyslipide...
Source: Annals of Internal Medicine - June 12, 2023 Category: Internal Medicine Authors: Marios Arvanitis Charles J Lowenstein Source Type: research
Cardiovascular risk in vasculitis
Best Pract Res Clin Rheumatol. 2023 Jun 9:101831. doi: 10.1016/j.berh.2023.101831. Online ahead of print.ABSTRACTThe present review summarizes the burden, risk factors, biomarkers of and therapeutic consideration for cardiovascular disease in systemic vasculitis. Ischemic heart disease (IHD) and stroke are intrinsic features of Kawasaki disease, Takayasu arteritis, Giant Cell Arteritis (GCA), and Behcet's disease. The risk of IHD and stroke is increased in anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) and cryoglobulinemic vasculitis. Behcet's disease could present with venous thromboembolism. The risk of...
Source: Cell Research - June 11, 2023 Category: Cytology Authors: Durga Prasanna Misra Aman Sharma George A Karpouzas George D Kitas Source Type: research
Investigation of Combined Carotid Endarterectomy and Coronary Artery Bypass Graft Surgery Outcomes and Adverse Event Risk Factors in the Vascular Quality Initiative
CONCLUSIONS: Combined CEA and CABG provides excellent long-term mortality prevention in patients with co-existing severe coronary and carotid atherosclerosis. Simultaneous CEA and CABG provides equivalent stroke prevention and long-term survival to both a cohort of patients undergoing coronary revascularization within 5 years of CEA and patients undergoing isolated CEA or CABG in the literature. The two most impactful modifiable risk factors towards long-term stroke and mortality prevention for patients undergoing simultaneous CEA-CABG are patch placement at CEA site and adherence to statin medication therapy.PMID:37303074...
Source: Atherosclerosis - June 11, 2023 Category: Cardiology Authors: Ashley Penton Jonathan Lin Grant Kolde Matthew DeJong Matthew Blecha Source Type: research
Immediate Statin After Acute Stroke Reduces Disability Immediate Statin After Acute Stroke Reduces Disability
Intensive statin therapy immediately after mild ischemic stroke or high-risk TIA reduces the risk for a poor functional outcome vs delaying 72 hours, the INSPIRES trial shows.Medscape Medical News
Source: Medscape Internal Medicine Headlines - June 9, 2023 Category: Internal Medicine Tags: Neurology & Neurosurgery News Source Type: news
Rates of Stroke in Patients With Different Presentations of Carotid Artery Stenosis
CONCLUSION: This cohort study showed no large differences in stroke rates among people with different presentations of carotid artery stenosis.PMID:37295600 | DOI:10.1016/j.ejvs.2023.05.041
Source: PubMed: Eur J Vasc Endovasc ... - June 9, 2023 Category: Surgery Authors: Dylan R Morris Tejas P Singh Tahmid Zaman Ramesh Velu Francis Quigley Jason Jenkins Jonathan Golledge Source Type: research
Can ‘toxic’ bilirubin treat a variety of illnesses?
Generations of medical and biology students have been instilled with a dim view of bilirubin. Spawned when the body trashes old red blood cells, the molecule is harmful refuse and a sign of illness. High blood levels cause jaundice, which turns the eyes and skin yellow and can signal liver trouble. Newborns can’t process the compound, and although high levels normally subside, a persistent surplus can cause brain damage.
Yet later this year up to 40 healthy Australian volunteers may begin receiving infusions of the supposedly good-for-nothing molecule. They will be participating in a phase 1 safety trial, sponsored ...
Source: ScienceNOW - June 8, 2023 Category: Science Source Type: news
